News

DIL is a world leader in developing and providing the finest products in food technology today. Under the terms of the agreement, DIL will manufacture and supply Fortetropin

TransCelerate BioPharma Inc. is dedicated to making the research and development process more efficient across the pharmaceutical industry. The Shared Investigator Platform, which will be built as an

CanTx and Novogen expect to file an Investigational New Drug (IND) application for Cantrixil early next year and to advance this compound into the clinic by mid- 2015.

The CHMP opinion supports the use of Zydelig in combination with rituximab for the treatment of adult patients with CLL who have received at least one prior therapy

The CHMP recommendation for Imbruvica is to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukemia (CLL) who have

The deal will see the development and scale-up of a new affinity resin and associated manufacturing process to improve the quality and purity of an existing biopharmaceutical product

The multicenter, randomized, placebo-controlled Phase II trial will evaluate the efficacy and safety of letermovir for the prevention of clinically-significant CMV infection in adult 18 years and older.

MGD007 is a Dual-Affinity Re-Targeting (DART) protein in development to treat colorectal cancer. The company will receive a $5m milestone payment from Servier, France’s largest privately-held pharmaceutical company,

The FDA concluded that the company’s testosterone product is therapeutically equivalent to AbbVie’s AndroGel 1% and can be substituted with the full expectation that it will produce the